Corvus publishes final Phase 1/1b soquelitinib data in Blood supporting Phase 3 relapsed/refractory PTCL trial

Reuters2026/08/27 11:31

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Corvus reported peer-reviewed final Phase 1/1b data for soquelitinib in T-cell lymphoma published in Blood; results were previously generated, not future-presented.
Study showed durable anti-tumor activity in heavily pre-treated patients, including complete responses, with a tolerable safety profile.
Findings support ongoing registration Phase 3 testing in relapsed or refractory peripheral T-cell lymphoma versus physician’s choice chemotherapy options.
Mechanism data linked activity to immune rebalancing effects in blood and tumor samples, supporting expansion into inflammatory diseases.
Company is enrolling a Phase 2 trial in atopic dermatitis, with additional trials planned in hidradenitis suppurativa and asthma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corvus Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608270730PRIMZONEFULLFEED9816961) on August 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Corvus publishes final Phase 1/1b soquelitinib data in Blood supporting Phase 3 relapsed/refractory PTCL trial

You may also like

Crypto prices